Idera Pharmaceuticals, Inc.
NASDAQ: IDRA0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Vincent J. Milano
- Employees
- 13
- Headquarters
- Exton, United States
- IPO year
- 1996
- Website
- https://www.iderapharma.com
Loading IDRA…
Loading profile data…Frequently asked questions about IDRA
What does Idera Pharmaceuticals, Inc. (IDRA) do?
Idera Pharmaceuticals, Inc. is a biopharmaceutical company committed to the research, development, and commercialization of medicines addressing rare diseases within the United States. A key offering is Tilsotolimod (IMO-2125), a proprietary synthetic phosphorothioate oligonucleotide. This compound functions as a direct TLR9 agonist, designed to...
Where does IDRA trade?
Idera Pharmaceuticals, Inc. (IDRA) trades on the NASDAQ Capital Market.
What sector is IDRA in?
Idera Pharmaceuticals, Inc. (IDRA) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Idera Pharmaceuticals, Inc.?
Vincent J. Milano is the chief executive officer of Idera Pharmaceuticals, Inc. (IDRA).
Where is Idera Pharmaceuticals, Inc. headquartered?
Idera Pharmaceuticals, Inc. is headquartered in United States.
Does IDRA pay a dividend?
Idera Pharmaceuticals, Inc. (IDRA) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IDRA go public?
Idera Pharmaceuticals, Inc. (IDRA) completed its initial public offering in 1996.